NASDAQ:EMBC - Nasdaq - US29082K1051 - Common Stock - Currency: USD
10.91
-0.43 (-3.79%)
The current stock price of EMBC is 10.91 USD. In the past month the price decreased by -14.9%. In the past year, price increased by 5.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 29.96 | 45.66B | ||
COO | COOPER COS INC/THE | 20.88 | 15.74B | ||
ALGN | ALIGN TECHNOLOGY INC | 18.44 | 12.61B | ||
SOLV | SOLVENTUM CORP | 9.56 | 11.06B | ||
LNTH | LANTHEUS HOLDINGS INC | 14.84 | 6.89B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 25.75 | 5.29B | ||
BLCO | BAUSCH + LOMB CORP | 19.44 | 4.26B | ||
ICUI | ICU MEDICAL INC | 21.98 | 3.36B | ||
HAE | HAEMONETICS CORP/MASS | 13.48 | 2.86B | ||
XRAY | DENTSPLY SIRONA INC | 7.68 | 2.55B | ||
UFPT | UFP TECHNOLOGIES INC | 27.71 | 1.62B | ||
NEOG | NEOGEN CORP | 12.34 | 1.02B |
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 2,100 full-time employees. The company went IPO on 2022-03-21. The firm has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. The company sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company also sells safety insulin syringes. The company distributes its products through a variety of channels, including retail, hospitals and pharmacies.
EMBECTA CORP
300 Kimball Drive, Suite 300
Parsippany NEW JERSEY US
Employees: 2200
Company Website: https://www.embecta.com/
Investor Relations: https://investors.embecta.com/
Phone: 18624010000
The current stock price of EMBC is 10.91 USD. The price decreased by -3.79% in the last trading session.
The exchange symbol of EMBECTA CORP is EMBC and it is listed on the Nasdaq exchange.
EMBC stock is listed on the Nasdaq exchange.
9 analysts have analysed EMBC and the average price target is 21.47 USD. This implies a price increase of 96.8% is expected in the next year compared to the current price of 10.91. Check the EMBECTA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EMBECTA CORP (EMBC) has a market capitalization of 634.20M USD. This makes EMBC a Small Cap stock.
EMBECTA CORP (EMBC) currently has 2200 employees.
EMBECTA CORP (EMBC) has a resistance level at 11.74. Check the full technical report for a detailed analysis of EMBC support and resistance levels.
The Revenue of EMBECTA CORP (EMBC) is expected to decline by -2.29% in the next year. Check the estimates tab for more information on the EMBC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EMBECTA CORP (EMBC) has a dividend yield of 5.29%. The yearly dividend amount is currently 0.6. Check the full fundamental report for a detailed analysis of EMBC dividend history, reliability and sustainability.
EMBECTA CORP (EMBC) will report earnings on 2025-05-09, before the market open.
The PE ratio for EMBECTA CORP (EMBC) is 4.35. This is based on the reported non-GAAP earnings per share of 2.51 and the current share price of 10.91 USD. Check the full fundamental report for a full analysis of the valuation metrics for EMBC.
The outstanding short interest for EMBECTA CORP (EMBC) is 3.88% of its float. Check the ownership tab for more information on the EMBC short interest.
ChartMill assigns a fundamental rating of 6 / 10 to EMBC. EMBC scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months EMBC reported a non-GAAP Earnings per Share(EPS) of 2.51. The EPS increased by 47.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.25% | ||
ROA | 5.06% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 51% to EMBC. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 15.79% and a revenue growth -2.29% for EMBC